Full-service contract research organization (CRO) SynteractHCR will exhibit at the 2nd annual DPharm Europe: Disruptive Innovations to Advance Clinical Trials event Feb. 9-10 in London, and will also present and exhibit at Outsourcing in Clinical Trials West Coast 2016 (OCT West Coast) Feb. 10-11 in San Mateo, Calif. The company’s growing international footprint, particularly in the U.S. and Europe, necessitates sharing intellectual capital at global industry events in 2016.
The DPharm Europe conference focuses on global examples of disruptive ideas and applying digital technologies to advance clinical trials. SynteractHCR’s team of experts will be in attendance to discuss the company’s experience in collaborating with emerging to mid-sized pharma, biotech and device companies to help efficiently bring tomorrow’s treatments to the patients who need them. Those interested in scheduling an appointment with the SynteractHCR team may contact Senior Director of Business Development Tony Dean at +44 (0)7771 846186.
At OCT West Coast, SynteractHCR will exhibit at booth #73 and discuss its global Phase I-IV capabilities. On Thursday, Feb. 11 at 9:30 a.m., Senior Regulatory Affairs Manager Thomas Christensen will present, “Preparing Proactively for FDA Mandated eCTD Submissions.” Because the FDA will require electronic common technical document (eCTD) submissions starting in 2017, attendees will learn how to streamline eCTD preparation as it becomes the standard submission format. The presentation will cover:
Attendees interested in meeting with the SynteractHCR team at OCT West Coast may contact Executive Director of Business Development Kim Martinez at 760-529-3440.
See SynteractHCR's full schedule of events and follow its social channels on LinkedIn and Twitter for live updates during all conferences.
SynteractHCR is a full-service contract research organization with a successful two-decade track record supporting biotechnology, medical device and pharmaceutical companies in all phases of clinical development. SynteractHCR has conducted Phase I-IV studies on six continents and 60 countries, offering expertise across multiple therapeutic areas, with notable depth in oncology, immunotherapy, CNS, infectious disease, endocrinology, cardiovascular and respiratory, among other indications. With its “Shared Work – Shared Vision” philosophy, SynteractHCR provides customized services collaboratively and cost effectively, ensuring on-time delivery of quality data to help bring tomorrow’s treatments to patients.